AzTrials
AzTrials

Type 2 DiabetesDiabColdHeatNCT04698200

Type 2 Diabetes, Cardiovascular Comorbidity and Environmental Temperature

A study testing Cold exposure in people with Type 2 Diabetes, run by University of Oulu at 1 site in Finland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Both high and low environmental temperatures are associated worldwide with higher morbidity and mortality and an estimated 8% of the mortality is estimated to relate to non-optimum temperatures. Read more about this study

Who is it for?
Ages 40 to 70 years, men onlyHealthy volunteers can take part
Conditions the study is for
Type 2 Diabetes
What is being tested?
Cold exposure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteFinland
Study dates
1 Jan 2021to Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Non-smoking
  • Type 2 diabetes
  • Hypertension

Who cannot join

  • Smoking
  • Chronic respiratory diseases
  • Coronary artery diseases

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • University of Oulu, Center for Environmental and Respiratory Health Research

    Oulu, FI-90014

Other trials in Finland

About this study

Official title: Type 2 Diabetes, Cardiovascular Comorbidity and Environmental Temperature: Randomized Controlled Study

Both high and low environmental temperatures are associated worldwide with higher morbidity and mortality and an estimated 8% of the mortality is estimated to relate to non-optimum temperatures. The majority of the adverse health effects occur at to low, and not high temperatures, and already with a modest change in temperature. Persons with type 2 diabetes can be sensitive to the effect of temperature due to their altered neural, metabolic and circulatory functions. The pathophysiological responses of type 2 diabetes in a cold and hot environment are not known.

The aim of the study is to examine how advanced type 2 diabetes (disease progression >10 years) alone, an in conjunction with coronary artery diseases and hypertension affect neural, cardiovascular and metabolic responses in a cold and hot environment.

Read more

Type 2 diabetes is associated with altered neural regulation, weakened cardiovascular function, structural changes in blood vessels, altered blood constitution and metabolic disturbances. These affect thermoregulation and result in increased susceptibility to cold (lesser heat production, increased heat loss) and heat (lesser sweating and heat loss).

The patients are exposed under controlled conditions in a random order to both cold (+10°C) and heat (+44°C) while resting and lightly clothed for 90 min at a time. The exposure itself is preceded by baseline measurements of the parameters of interest, and followed by repeating the same measurements after the exposure.

The topic of the research is very relevant due to the worldwide epidemic of type 2 diabetes. Simultaneously, the comorbid conditions associated with diabetes become more common and are related to a higher occurrence of cardiac events. The research information is useful for all individuals with type 2 diabetes in their protection and self-management of the disease, and enabling to maintain functional ability in a cold or hot environment. The research knowledge can be utilized when developing weather warning systems for the identification of susceptible populations. Health care personnel may utilize the research information while advising their patients and for proper care. An increased awareness of the health effects of both low and high temperatures improve the functional ability of individuals and reduced help reducing morbidity and mortality from weather conditions.

Read the detailed description

Significance of the project in relation to current knowledge Temperature, health and climate change. Both high and low and environmental temperatures cause discomfort and degradation of physical performance. These normal physiological responses elicited to lose or preserve body heat can aggravate the course of chronic diseases and lead to a higher amount of health care visits, hospitalizations, or deaths. Globally, most of the adverse health effects are caused by cold, rather than heat, and occur already at mild non-optimal temperatures.

Environmental temperatures reflect the primary effects of climate change (CC), the biggest health threat of the 21st century. CC primarily involves a global increase of temperatures, and especially in the frequency, intensity and duration of heat extremes. Connected to the variability of weather, also higher amounts of precipitation, clouds, and winds are predicted. Northern climates, such as Finland, are subjects to huge annual variations in temperature (from ca. +30°C to -30°C) together with periodic prolongation of temperature extremes (heat and cold spells). Global projections predict that health effects of cold continue to outnumber those of heat in Finland, but heat exposure becomes increasingly important, also due to the lack of adaptation to high temperatures of northern residents.

T2D and temperature. The global occurrence of diabetes is 425 million people of which 77% are working aged and is estimated to increase to 629 million people by 2045. Type 2 diabetes (T2D) accounts for 90% of the diabetic patients. In Finland, the incidence of T2D has increased markedly in men for the last 35 years. Diabetes of all types can lead to micro- (retino-, nephro- and neuropathies) and macrovascular (cerebral, coronary and peripheral arterial disease) complications and resulting in higher morbidity and premature deaths. The economic burden of the direct and indirect costs of diabetes is tremendous and represented 1.8% of the GDP in 2015.

Epidemiological studies suggest that non-optimal environmental temperatures and diabetes are associated with higher morbidity and mortality. A study of 4.5 Million GP consultations showed that persons having T2D sought medical attention more often with both low and high temperatures. Furthermore, cold and hot temperatures were associated with a 12% and a 30% increase in diabetes-related hospitalizations.

Heat exposure may involve a lesser ability to lose additional body heat (higher heat load) to the environment and higher cardiovascular strain.

To our knowledge, there are only three controlled studies that have assessed whole-body heat exposure among persons with T2D. In healthy persons high temperatures dilates superficial blood vessels enabling conveying additional body heat to the environment. Consequently, blood flow is directed to the body surface augmenting heart rate and cardiac workload. In persons with T2D the dilation of the blood vessels may be delayed and lead to diminished capacity to lose heat through skin circulation. In addition, disrupted endothelial function and stiffening of blood vessels can lead to an attenuated reduction in blood pressure. Factors, such as reduced sweating capacity, as well as autonomic and peripheral neuropathies may further impair the ability to lose body heat to the environment. In fact, a study involving older adults with T2D detected reduced capacity to lose additional body heat during exercise, resulting in greater thermal strain. Also, cardiac regulation and ability to increase cardiac workload could be impaired in T2D under exposure to heat. Supporting this, older (ca. 60 yrs.) persons with T2D showed reduced heart rate variability and response to heat. Lastly, hypercoagulation of persons with T2D could be further increased during heat exposure, but there are no studies of the topic.

Cold exposure may involve higher cardiovascular strain and a reduced ability to produce or preserve (increased heat loss) body heat in cold weather in persons with T2D.

There are no previous controlled studies which assess the effects of whole-body cold exposure among persons with T2D. In healthy persons exposure to low temperature increases sympathetic activity which constricts superficial blood vessels, results in elevated blood pressure and cardiac workload. The aggravated blood pressure increase in persons with T2D can be due to sympathetic over activity, disrupted endothelial function and stiffer arteries. The altered neural regulation in T2D may impair cardiac responsiveness to the higher cardiac workload and oxygen demand in cold. Cold exposure also increase blood coagulation potential, which together with hypercoagulability related with T2D, could promote the production of thromboses and adverse cardiac events. Microvascular dysfunction associated with autonomic neuropathy can also impair vascular responsiveness during local cooling and possibly increase susceptibility to low temperatures. Cold exposure may also be related to reduced heat production (shivering thermogenesis or reduction in brown adipose tissue activity and mass).

Modifying factors possibly affecting vulnerability to high or low temperature of T2D High blood pressure is reported in over two-thirds of patients with T2D and the incidence of diabetes and hypertension (HTN) predicts each other over time. The two diseases share common metabolic abnormalities and insulin resistance is a characteristic of both prediabetes and prehypertension. Like diabetes, also cardiovascular diseases are temperature sensitive. Glycemic control may be important for coping with thermal stress, but the available evidence is scarce. Heat exposure, especially when combined with exercise, can induce hypoglycemia. On the other hand, a brief acclimation period to repeated mild cold exposure can improve insulin sensitivity and glycemic state. Medication associated with both treatment of T2D itself (metformin, gliptines, gliflotsines) or HTN (beta-blockers, diuretics, calcium-channel blockers, ACE-inhibitors), could significantly affect cardiovascular and thermal responses, but their association with health outcomes are not known. Regular physical activity itself reduces HbA1c, but may also improve heat dissipation capacity, but the mechanisms are unclear.

Our aims are:1) Assess how advanced T2D in combination with hypertension, influences cardiovascular function and associated neural, and metabolic responses during whole-body passive exposure to heat (activating heat loss through higher superficial circulation and sweating) and cold (causing increase in heat production and reduction in superficial circulation) and compared with healthy persons. 2) Eamine how different diabetic micro- and macrovascular complications involving varying degrees of severity, affect the observed cardiovascular, neural and metabolic functions while exposed to either cold or heat. 3) Assess how T2D (diagnosed or detected during clinical examination) alone, and in combination with hypertension (diagnosed or measured during clinical examination) affect reported cold- or heat-related cardiorespiratory symptoms and consequently, from a longitudinal perspective, hospitalizations and mortality. We also aim to identify the influence of potential determinants, such as the use of medication, physical activity and other demographic, socioeconomic and lifestyle factors.

Research hypotheses: 1) Exposure of those with T2D may lead to earlier heat strain due to reduced ability to lose (reduced sweating and circulation) bodily heat at high temperatures. 2) Exposure to cold may lead to earlier cold strain due to weakened ability to preserve (impaired circulation) or produce bodily heat (shivering) at low temperatures. 3) Having more complications increase the vulnerability to these environments. 4) At the population level, people with T2D report more heat- and cold-related cardiorespiratory symptoms and experience more hospitalizations and deaths. These effects are dependent on the glycemic and blood pressure control, use of medication and other lifestyle factors. 5) Health care visits and mortality are preceded by temperatures that are higher or lower than average.

Conditions
Type 2 Diabetes
Being tested
Cold exposure
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cold exposureOther

    Also called Heat exposure

    Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.

Study groups in NCT04698200
Study groupRoleWhat they receive
Blood pressureExperimentalMeasurement of brachial, central and beat-to-beat blood pressure.
Receives: Other: Cold exposure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of systolic and diastolic blood pressure

    Brachial, central and beat-to-beat systolic and diastolic blood pressure

    Measured: 10, 20 and 30 minutes before the intervention, during the intervention in 10 minutes intervals, and 5, 10, 15, 20 25 and 30 minutes after the intervention.

Secondary outcomes (4)
  1. Electrocardiogram, ECG

    Continuous 15-channel recording during the intervention to detect ST elevation.

    Measured: 3 hours

  2. Metabolic rate

    Measurement of oxygen consumption.

    Measured: During the 60 minutes intervention period.

  3. Sweating

    Measurement of total sweating rate.

    Measured: During the 60 minutes intervention period and immediately after the intervention.

  4. Skin and body temperature

    Continuous measurement of skin and body temperatures.

    Measured: 3 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2021
  2. Study start1 Jan 2021
  3. Primary completionDec 2023 (estimated)
  4. Study completionDec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04698200
Sponsor's protocol ID
DiabColdHeat
Acronym
DiabColdHeat
Status last verified
Jun 2021
First submitted
23 Nov 2020
Last updated
18 Jun 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Cold exposure in people with Type 2 Diabetes, run by University of Oulu at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of systolic and diastolic blood pressure (time frame: 10, 20 and 30 minutes before the intervention, during the intervention in 10 minutes intervals, and 5, 10, 15, 20 25 and 30 minutes after the intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in